Cadila Healthcare: The right remedy - Buy
The large pipeline of drugs awaiting regulatory nod should boost revenues20-03-2016
20-03-2016
Zydus Cadila gets US FDA nod to market Clofarabine Injection
Healthcare player Zydus Cadila (Cadila Healthcare Limited) on Wednesday announced that the company has received the tentative approval from the US Drug Regulator, USFDA to market its Clofarabine Inje...09-03-2016
Zydus receives tentative approval from the USFDA for Clofarabine Injection
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated March 09, 2016 titled "Zydus receives tentative approval from the USFDA for Clofarabine Injection".09-03-2016
Fixes Record Date for Interim Dividend
Cadila Healthcare Ltd has informed BSE that the Company has fixed March 18, 2016 as the Record Date for the purpose of Payment of Interim Dividend.Further, the interim dividend shall be paid to the members entitled thereto, on and from March 23, 2016. The Dividend cheques would be posted on or after March 23, 2016 and within 30 days from the date of declaration of dividend as provided in the Companies Act, 2013.08-03-2016
Board declares Interim Dividend
Cadila Healthcare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 08, 2016, has declared an interim dividend of Rs. 3.20/- [i.e. @ of 320%] per Equity Share on 102,37,42,600 Equity Shares of Rs. 1/- each of the Company for the financial year 2015-2016.08-03-2016
Board to consider Interim Dividend
Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on March 08, 2016, inter alia, to consider, declaration of Interim Dividend for the financial year 2015-16 and to fix the Record date.Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window shall remain closed from March...01-03-2016
Cadila Healthcare gains on USFDA nod for anti-diabetic drug
The company has received final approval from the USFDA for Glyburide and Metformin Hcl tablets USP01-03-2016
Zydus receives final approval from the USFDA for Glyburide and Metformin Hcl Tablets USP
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated March 01, 2016 titled "Zydus receives final approval from the USFDA for Glyburide and Metformin Hcl Tablets USP".01-03-2016
Zydus to commence supplies to the US market from its formulation manufacturing facility at SEZ
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 19, 2016 titled "Zydus to commence supplies to the US market from its formulation manufacturing facility at SEZ".19-02-2016
Subdued growth outlook for Cadila
After FDA warning letter for its Moraiya unit, new product approvals after site transfers might take 2-3 quarters08-02-2016